The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Antibody Fragments Market During 2026–2030?
The antibody fragments market size has shown significant expansion in recent times. It is predicted to increase from $11.26 billion in 2025 to $12.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The previous period’s growth stemmed from factors including advancements in monoclonal antibody technologies, the clinical efficacy of antibody-derived treatments, a rise in cancer biologics research, expanded applications of diagnostic antibodies, and heightened investment in biologics R&D.
The antibody fragments market is set for significant expansion in the next few years. It is projected to grow to $17.56 billion by 2030, at a compound annual growth rate (CAGR) of 9.3%. This anticipated growth can be attributed to the rise in targeted cancer therapies, the expansion of antibody fragment pipelines, increasing demand for precision biologics, a growing use in companion diagnostics, and innovation in recombinant antibody engineering. Major trends foreseen during this period include the increasing adoption of fragment-based biologics, their expanded application in oncology and targeted therapies, a rising demand for high-penetration antibody formats, the broadening of diagnostic applications, and an increased focus on treatments that offer reduced immunogenicity.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23307&type=smp
Which Economic Or Industry Drivers Are Impacting The Antibody Fragments Market?
The expanding occurrence of target diseases is projected to drive the growth of the antibody fragments market. Target diseases are specific illnesses or health conditions that a medicine, treatment, or medical research seeks to prevent, manage, or cure. Prominent target diseases include cancer, infectious diseases, and bacterial infections. This increasing prevalence of target diseases primarily stems from unhealthy lifestyles and pollution, which weaken the body’s defenses and lead to chronic conditions. Antibody fragments offer highly specific, targeted, and versatile options for treating various diseases, often with reduced side effects compared to traditional therapies. Their ability to be customized and engineered for specific targets makes them an increasingly valuable tool in modern medicine. For instance, in January 2025, a report published by the American Cancer Society, a US-based non-profit organization, indicated that the United States is expected to report 2,041,910 new cancer cases and 618,120 cancer deaths in 2025, an increase from 2,001,140 new cases and 611,720 deaths in 2024. Therefore, the rising prevalence of target diseases is a significant driver for the growth of the antibody fragments market.
How Are The Various Segments Of The Antibody Fragments Market Categorized?
The antibody fragments market covered in this report is segmented –
1) By Type: F(ab) Fragments, F(ab’)2 Fragments, Single-Chain Variable Fragments (scFvs), Single Domain Antibody Fragments (sdAbs), Other Types
2) By Specificity: Monoclonal Antibody, Polyclonal Antibody
3) By Delivery Method: Intravenous (IV), Subcutaneous (SC)
4) By Application: Cancer, Immunodeficiencies, Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Diagnostic Laboratories, Contract Research Organizations (CROs)
Subsegments:
1) By F(ab) Fragments: Recombinant F(ab) Fragments, Enzymatically Derived F(ab) Fragments
2) By F(ab’)2 Fragments: Pepsin-Derived F(ab’)2 Fragments, Recombinant F(ab’)2 Fragments
3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs), Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs), Yeast-Produced Single-Chain Variable Fragments (scFvs)
4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs), Shark-Derived Single Domain Antibody Fragments (sdAbs), Synthetic Single Domain Antibody Fragments (sdAbs)
5) By Other Types: Bispecific Antibody Fragments, Multispecific Antibody Fragments, Fusion Protein Antibody Fragments
What Trends Are Affecting The Expansion Of The Antibody Fragments Market?
Leading companies within the antibody fragments market are concentrating on conducting clinical trials aimed at developing innovative products, such as human VH antibody fragments, to improve the effectiveness of targeted therapy and decrease immunogenicity in the treatment of cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment is defined as the variable domain of a human antibody’s heavy chain, capable of independently binding to antigens. It plays a vital role in forming antibody fragments by serving as the essential antigen-binding region, frequently utilized alone or fused with other molecules to create small, stable, high-affinity therapeutic or diagnostic antibodies. For instance, in May 2024, Zai Lab Limited, a China-based pharmaceutical company, launched a global Phase 2 clinical trial to evaluate the efficacy and safety of ZL-1102. ZL-1102 is a novel human VH antibody fragment (Humabody) specifically designed to target IL-17. It is currently being developed as a topical therapy for mild-to-moderate chronic plaque psoriasis, seeking to enhance treatment precision while simultaneously reducing systemic side effects and immunogenic responses.
Which Major Firms Influence Developments In The Antibody Fragments Market?
Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.
Read the full antibody fragments market report here:
https://www.thebusinessresearchcompany.com/report/antibody-fragments-global-market-report
What Are The Top-Performing Regions Within The Antibody Fragments Market?
North America was the largest region in the antibody fragments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody fragments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antibody Fragments Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23307&type=smp
Browse Through More Reports Similar to the Global Antibody Fragments Market 2026, By The Business Research Company
Antibody Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report
Polyclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report
Research Antibodie And Reagent Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model